1. Male or female of any race, at least 18 years of age at Visit 1 Screening. 
2. Has provided verbal and written informed consent. 
3. Be able and willing to follow instructions, including participation in all study assessments and visits. 
4. Currently being treated for glaucoma using at least two medications, and be willing to continue on the same regime. 
5. Suffers from at least two of the symptoms in the GLIA™ Glaucoma Medication Ocular Side Effect Symptoms Questionnaire at a severity of 2 (moderate) or more. 
6. If a woman of childbearing potential, have a negative urine pregnancy test at Visit 1 and be using an adequate method of birth control throughout the study period. 

NCT02656394_inc_T7
Person
Male
NCT02656394_inc_T8
Person
female
NCT02656394_inc_T9
Value
at least 18 years
NCT02656394_inc_T10
Person
age
NCT02656394_inc_T11
Temporal
at Visit 1 Screening
NCT02656394_inc_T12
Reference_point
Visit 1 Screening
NCT02656394_inc_T17
Condition
glaucoma
NCT02656394_inc_T18
Procedure
treated
NCT02656394_inc_T19
Temporal
Currently
NCT02656394_inc_T20
Multiplier
at least two
NCT02656394_inc_T21
Drug
medications
NCT02656394_inc_T24
Multiplier
at least two
NCT02656394_inc_T25
Condition
symptoms
NCT02656394_inc_T26
Measurement
GLIA™ Glaucoma Medication Ocular Side Effect Symptoms Questionnaire
NCT02656394_inc_T27
Value
severity of 2 or more
NCT02656394_inc_T28
Value
moderate
NCT02656394_inc_T29
Person
woman
NCT02656394_inc_T30
Condition
childbearing potential
NCT02656394_inc_T31
Measurement
urine pregnancy test
NCT02656394_inc_T32
Value
negative
NCT02656394_inc_T33
Temporal
at Visit 1
NCT02656394_inc_T34
Reference_point
Visit 1
NCT02656394_inc_T35
Device
method of birth control
NCT02656394_inc_T36
Qualifier
adequate
NCT02656394_inc_T38
Temporal
throughout the study period
NCT02656394_inc_T39
Reference_point
study period